Home | Volume 52 | Article number 87

Research

Predictive factors of radioactive iodine therapy failure in hyperthyroidism: a retrospective study of 171 patients

Predictive factors of radioactive iodine therapy failure in hyperthyroidism: a retrospective study of 171 patients

Skander Chaabouni1,&, Imen Meddeb2, Marwa Somai2, Asma Krir1, Mehdi Mrad1, Afef Bahlous1, Aida Mhiri2

 

1Institut Pasteur de Tunis, Clinical Biochemistry and Hormonology Laboratory, Gouvernorat de Tunis, Tunis, Tunisia, 2Salah-Azaïz Institute, Nuclear Medicine Department, Gouvernorat de Tunis, Tunis, Tunisia

 

 

&Corresponding author
Skander Chaabouni, Institut Pasteur de Tunis, Clinical Biochemistry and Hormonology Laboratory, Gouvernorat de Tunis, Tunis, Tunisia

 

 

Abstract

Introduction: radioiodine therapy with iodine-131 is a standard treatment for hyperthyroidism. Nevertheless, the variability in individual response underscores the need to identify reliable predictors of treatment failure. The study aimed to determine the clinical and biological factors associated with the failure of the first course of radioactive iodine therapy in hyperthyroid patients.

 

Methods: this was a retrospective cohort study conducted between 2012 and 2018, including 171 patients treated for hyperthyroidism with radioiodine therapy at the Salah Azaiez Institute. Demographic, clinical, biological, and therapeutic data were collected and analysed.

 

Results: the median age was 49 years, with a female predominance (sex ratio: 0.41). Graves' disease accounted for 73.7% of cases, and resistance to antithyroid drugs was the main indication for radioiodine therapy (68%). A fixed dose of iodine-131 was administered (mean: 14 ± 2.6 mCi). Treatment failure after the first course occurred in 22.2% of patients (n=38). Failure was significantly associated with higher administered doses (p=0.007), TSH receptor antibody positivity (p=0.005), and the presence of ophthalmopathy (p=0.013).

 

Conclusion: failure after radioiodine therapy appears to be influenced by biological markers (TSH receptor antibodies) and specific clinical factors (ophthalmopathy). These results support individualised dosing strategies and highlight the need for multicenter studies to standardise treatment protocols in nuclear medicine centers in Tunisia.

 

 

Introduction    Down

Hyperthyroidism (HT) is a common endocrinopathy, defined by elevated free thyroid hormones and resulting in a thyrotoxic syndrome whose clinical manifestations vary according to the underlying aetiology [1,2]. It can occur at any age and may lead to significant systemic and psychosocial consequences, warranting prompt and appropriate management. Diagnosis is based on hormonal assays, complemented by the detection of autoantibodies to determine the aetiology, most commonly Graves' disease. Treatment options include antithyroid drugs, surgery, and radioactive iodine (ąłąI), the latter increasingly used as a first-line therapy in certain contexts [3]. However, the response to radioiodine therapy varies considerably among patients, emphasising the need to identify reliable clinical and biological predictive factors [4,5]. In the absence of large-scale local data, we conducted this study in the Department of Nuclear Medicine at the Salah Azaiez Institute, aiming to determine the clinico-biological factors associated with the response to ąłąI therapy in patients with hyperthyroidism.

 

 

Methods Up    Down

Study design: this was a retrospective, observational, single-centre study conducted between January 2012 and December 2018.

Setting: the study was conducted at the Department of Nuclear Medicine, Salah Azaiez Institute, Tunis, Tunisia, between January 2012 and December 2018. This semi-public tertiary care centre receives patients from across the country. All patients referred for radioactive iodine therapy during this period were included in the study. Clinical, biological, and imaging data were retrospectively collected from medical records using a standardised collection form. Follow-up assessments were performed at 3 and 6 months after the first course of radioactive iodine therapy, including measurement of thyroid-stimulating hormone (TSH) and free thyroxine (FT4) levels, to evaluate treatment response.

Participants: all patients treated for hyperthyroidism with radioactive iodine (iodine-131) who had documented clinical and biological follow-up after therapy were included. Hyperthyroidism was confirmed by suppressed TSH with elevated T3 and/or free T4 levels. Exclusion criteria were: concomitant thyroid malignancy, absence of significant tracer uptake on thyroid scintigraphy, lack of pre- or post-therapeutic biological follow-up, incomplete medical records, and age under 18 years. A total of 171 patients were included.

Variables: the primary outcome was resistance to radioiodine therapy, defined as persistent hyperthyroidism (TSH below reference values) at 6 months after the first course. Secondary outcomes included early response (TSH above reference at 3 months) and favourable response (TSH above reference at 6 months). Explanatory variables: age, sex, medical history, duration of symptoms, aetiology of hyperthyroidism (Graves', nodular, iatrogenic, other), prior antithyroid drug therapy (type, dose), clinical manifestations (weight loss, heat intolerance, cardiovascular, neuropsychiatric, gastrointestinal symptoms), presence of exophthalmos, administered radioiodine dose, and scintigraphic findings.

Data sources/measurement: data were extracted from medical records using a standardised collection form. Thyroid scintigraphy was systematically performed on the day of iodine administration, approximately 20 minutes after intravenous technetium-99m injection, to confirm tracer uptake and guide therapeutic decisions. Patients fasted for at least two hours before therapy to optimise iodine bioavailability. Radioiodine was administered orally, either as a capsule or liquid solution, with sufficient water. The administered activity was determined based on hyperthyroidism severity and scintigraphic pattern, following the French Society of Nuclear Medicine recommendations.

Bias: selection bias was minimised by including all eligible patients during the study period. Information bias was reduced by using standardised methods for clinical, biological, and imaging assessments.

Study size: no a priori sample size calculation was performed; all eligible patients were included in the study.

Quantitative variables: continuous variables such as age were expressed as mean ± standard deviation or median [interquartile range], depending on distribution. Follow-up time points (3 and 6 months) were analysed for early and favourable response evaluation.

Statistical methods: data were entered into Excel and analysed using SPSS version 20.0. Comparisons were made using Student's t-test or Mann-Whitney test for continuous variables, and chi-square or Fisher's exact test for categorical variables, as appropriate. Multivariate logistic regression was used to identify factors independently associated with treatment failure (p < 0.05 considered significant). Correlations between continuous variables were assessed using Pearson or Spearman tests. Data confidentiality was maintained throughout the study.

 

 

Results Up    Down

Participants: a total of 171 patients treated with radioactive iodine for hyperthyroidism were included. Patients were excluded if they had concomitant thyroid malignancy, absent scintigraphic uptake, incomplete follow-up, or age under 18 years. The flow of participants through the study is summarised in Table 1.

Descriptive data: the mean age of the cohort was 48.8 ± 16.4 years, with a male-to-female sex ratio of 0.41 (mean age: 47.6 ± 16.8 years for women, 51.5 ± 15.1 years for men). Exophthalmos was observed in 17.5% of patients (n=29), one-third of whom required corticosteroid therapy. Baseline hormonal assessment showed thyrotoxicosis in the majority of cases: median free T4 (FT4) was 26 pmol/L [16-50], with 63.2% (n=108) exhibiting elevated FT4. Median TSH was 0.03 µIU/mL [0.03-0.05], with 97% (n=166) of patients having TSH < 0.1 µIU/mL. Thyroid autoantibodies were positive in 52% for anti-thyroperoxidase (anti-TPO, n=89) and 41.5% for TSH receptor antibodies (TRAb, n=71). The main indication for radioiodine therapy was antithyroid drug resistance (68%), followed by recurrence (6%), drug-induced toxicity (4%), and clinician preference for radical treatment (22%). Before therapy, 77% (n=133) had received antithyroid drugs.

Outcome data: the mean administered dose of iodine-131 for the first course was 14 ± 2.6 mCi (range 8-25 mCi). A second course was required in 21% (n=36) of patients, with a mean dose of 14.4 ± 3.1 mCi. Aetiology-specific doses were as follows:

Graves' disease (n=126): mean first-course dose 13.4 ± 2.1 mCi; 22.2% required a second course.

Toxic nodule (n=3): mean dose 15.6 ± 3.3 mCi; no second course required.

Multinodular goiters (n=17): initial mean dose 15.7 ± 3.5 mCi; 23.5% required a second course (18.25 ± 4.7 mCi).

Basdowe goiters (n=25): first-course mean dose 15.52 ± 2.43 mCi; 16% required a second course (17.5 ± 2.8 mCi).

Main results: biological follow-up at 3 months post-first course (n=97, 57%) showed early response (hypothyroidism) in 38% (n=37), normal TSH in 17%, and persistent hyperthyroidism in 45%. At 6 months (n=124), 70% of patients achieved a favourable response, while 30% experienced treatment failure (persistent hyperthyroidism). One patient lost to follow-up without TSH measurement at 6 months was considered a good responder. Predictive factors of treatment failure at 6 months after the first course are summarised in Table 2.

Other analyses: radioiodine therapy resistance was observed in 22.2% of patients (n=38). Multivariate analysis of factors influencing treatment response showed that, clinically, only the presence of ocular manifestations (exophthalmos) was significantly associated with resistance to therapy (p=0.013). Biologically, TSH receptor antibody (TRAb) positivity was correlated with therapy resistance (p=0.005). In univariate analysis, baseline TSH was significantly lower in patients who failed therapy (p=0.007), but this association did not persist in multivariate analysis. Therapeutically, the administered activity of iodine-131 during the first course was significantly associated with resistance (p=0.007). Other sociodemographic, clinical, and biological factors were not significantly associated with treatment response.

 

 

Discussion Up    Down

Table 3 summarises the most relevant studies evaluating predictive factors for response to radioactive iodine therapy in hyperthyroidism. This represents the largest national study evaluating the response to fixed-dose iodine-131 therapy in hyperthyroidism.

Summary of main findings: our study included 171 patients with hyperthyroidism referred for radioactive iodine therapy at the Salah Azaiez Institute. The main indications were resistance to antithyroid drugs (68%, n=116), recurrence of hyperthyroidism (6%, n=10), and drug-induced toxicity (4%, n=7). The remaining patients (22%, n=38) were referred according to the treating physician's choice for definitive isotopic treatment. Graves' disease was the most frequent aetiology, affecting 73.7% of the study population, with a clear female predominance across all etiologies. Fixed doses of radioactive iodine were administered, with a mean of 14 ± 2.6 mCi.

Treatment failure after the first course of radioactive iodine was observed in 22.2% of patients (n=38). Multivariate analysis showed that, clinically, only the presence of ocular manifestations was significantly associated with therapy resistance (p=0.013). Biologically, TSH receptor antibody (TRAb) positivity was correlated with resistance (p=0.005). In univariate analysis, baseline TSH was significantly lower in patients who failed therapy (p=0.007), but this association did not persist in multivariate analysis. Therapeutically, the administered activity of iodine-131 during the first course was significantly associated with resistance (p=0.007). Other sociodemographic, clinical, and biological factors were not significantly associated with treatment response.

Comparison with the literature: the mean age in our cohort was 48.8 ± 16.4 years, comparable to reports by Schneider et al. (43.4 ± 15.5 years) and Issami et al. (49.5 years) [6,7]. The aetiology of hyperthyroidism may vary with age: Graves' disease commonly occurs between 30 and 50 years, whereas toxic nodular goiter is more frequent after 50 years, and toxic adenoma tends to occur at younger ages [8,9]. Our series, dominated by Graves' disease, primarily involved patients aged 30-60 years.

No significant correlation was observed between age and response to iodine-131 (p=0.13), which may be explained by the use of fixed doses according to aetiology, itself influenced by age. Resistance was more frequent in patients under 35 years (40.5%), followed by those over 60 years (19.1%), whereas patients aged 35-49 years showed the highest response rate (85.1%). Several studies suggest that advanced age is associated with higher success rates [10-12].

As expected, hyperthyroidism was more frequent in women (F/M sex ratio = 2.43), consistent with previous reports [13-15], with no significant difference in treatment response between sexes. The most common clinical signs were general, neurological, and cardiovascular, in agreement with other series [6,15]. Orbitopathy was significantly associated with resistance to radioiodine therapy (p=0.013), as previously reported [16]. It may interfere with radioiodine uptake due to inflammation and anatomical changes [16]. Tachycardia has also been associated with treatment failure (p<0.01) [6].

Regarding aetiology, no significant correlation with treatment response was observed, consistent with other studies [6,13], although some authors suggest relative radioresistance in nodular forms [17-20], possibly due to persistent autonomous tissue with reduced uptake [17]. The predictive role of FT4 remains debated. Some studies report that elevated FT4 is associated with an increased risk of failure [3,9,18], but our findings, as well as those of others [21,22], did not show a significant relationship. Conversely, low TSH was associated with a higher rate of failure (significant univariate correlation), supporting data from Schneider [6]. Elevated TSH would enhance iodine uptake, thereby improving treatment efficacy. However, this correlation was not observed in studies by Husseni et al. and Aizawa et al. [23,24].

In our cohort, TRAb positivity in patients with Graves' disease was 48%, similar to several other studies [25], although Yassine et al. reported 100% positivity [19]. As classically reported, all patients with toxic nodules were TRAb-negative [25], while results for other etiologies remain variable [26]. Studies by Mathew John highlighted the diagnostic value of TRAb in hyperthyroidism [27]. In our study, TRAb positivity was significantly associated with resistance to radioiodine therapy (p=0.005), with an odds ratio of 3.79 (95% CI: 1.5-9.5), consistent with multiple publications [28,29]. This resistance may be explained by chronic stimulation of TSH receptors leading to glandular remodelling, such as fibrosis or inflammation, limiting iodine uptake [30]. However, other studies suggest an inverse association, linking TRAb positivity to better treatment outcomes [23]. Regarding anti-thyroperoxidase antibodies (anti-TPO), our study did not find a significant association with response to iodine-131, in agreement with previous reports [30]. Although frequently present in thyroid disorders, anti-TPO antibodies do not appear to directly influence treatment sensitivity.

Our cohort study revealed that all patients exhibited an unfavourable course under antithyroid drugs (ATD), defined by persistent or recurrent hyperthyroidism, or the occurrence of adverse effects. However, no significant correlation was observed between ATD use and response to radioiodine therapy, consistent with previous studies [31,32]. Some authors, nevertheless, have highlighted a potential radioprotective effect of ATDs, increasing the risk of therapeutic failure, particularly when administered immediately before the treatment [25]. This interference may result from a reduced radioactive iodine half-life, leading to suboptimal tissue exposure [33]. The type of ATD could also play a role, with some studies implicating specifically imidazoles [3], and others thio-uracil derivatives [34]. Furthermore, prolonged ATD use appears to be a factor of resistance in several studies [21]. Walter et al. recommend discontinuation at least one week before the treatment to improve its efficacy [35], a practice that was systematically applied in our series.

In this study, the main indication for radioiodine therapy was resistance to ATDs, as reported in several other series [2,4]. In other studies, intolerance or adverse effects of ATDs were the most frequent reasons for resorting to this therapy [4,7]. According to the National Institute for Health and Care Excellence (NICE) guidelines, radioiodine therapy is indicated as first-line treatment in thyrotoxicosis when ATDs are contraindicated or ineffective [36]. Since its introduction in 1941 [37], various therapeutic protocols have been proposed. In practice, the therapeutic target differs among centres, and no clear consensus exists regarding the optimal dose. Two strategies coexist: fixed doses based on aetiology, and calculated doses according to gland size and iodine uptake. Comparative studies of these approaches have produced conflicting results [38].

In our study, the nuclear medicine team at ISA used a standardised regimen, mainly based on aetiology. During the early years, adjustments were occasionally made according to age, hyperthyroidism severity, and socioeconomic context. In line with the latest American Thyroid Association (ATA) guidelines, a fixed and sufficient dose of iodine-131 (typically 10-15 mCi for autoimmune hyperthyroidism) should be administered in a single session [38]. These recommendations were followed in our series, with a mean dose of 14 mCi, comparable to that used in other studies [2,3]. Notably, we observed a negative correlation between the administered dose and therapeutic success (p<0.007; OR=0.778), in contrast with most previous studies reporting better response rates with higher doses, particularly in Graves' disease [2,25], as well as in toxic nodules and multinodular goiters [3,39,40]. This discrepancy may be explained by relative underdosing observed in our population for nodular etiologies, due to logistical constraints limiting access to sufficiently high activities. Treatment efficacy is generally proportional to the delivered absorbed dose, with recommended levels varying by aetiology: 130-200 Gy for uninodular goiters and 80-130 Gy for multinodular goiters [39]. Despite higher doses administered to patients with nodular etiologies, these remained below optimal thresholds. This situation could explain the more frequent failures observed in these subgroups compared to autoimmune forms.

The relationship between administered iodine dose, aetiology, and radioiodine therapy efficacy remains controversial. This variability likely results from differences in epidemiological profiles and etiological distribution among studies. In particular, the question of whether toxic nodules and multinodular goiters have higher failure rates than Graves' disease, and thus require higher doses, remains open [40,41]. Other factors should also be considered, such as renal clearance-which is reduced in renal insufficiency-or prior ATD treatment, both of which can alter the pharmacokinetics of radioactive iodine and thereby affect therapeutic efficacy.

Limitations: this study has several limitations. It is a single-centre, retrospective study, which may limit the generalizability of the findings. Some clinical and biological data were incomplete, and a few patients were lost to follow-up. Additionally, follow-up was limited to six months after the first course, preventing assessment of late hypothyroidism or delayed therapy failures. Variability in laboratory assay techniques across centres may also affect the comparability of results. Despite these limitations, all eligible patients during the study period were included, and standardised treatment and follow-up protocols were applied.

Clinical implications and perspectives: our study, conducted on a large national population-the largest to date in Tunisia-provides new insights into the relationship between administered iodine-131 activity and treatment efficacy in hyperthyroidism. The results emphasise the importance of adjusting administered doses to minimise the risk of treatment failure and optimise patient management. These findings support the need for prospective multicenter studies with standardised protocols, enabling better individualisation of therapy according to local practice and patient characteristics.

 

 

Conclusion Up    Down

Radioiodine therapy represents an effective, simple, and minimally invasive treatment option for hyperthyroidism. However, treatment response remains heterogeneous. In our study, several factors were identified as being associated with an increased risk of therapeutic failure, including orbitopathy, an initially suppressed TSH, and positivity for anti-TSH receptor antibodies. These findings support the implementation of an individualized strategy that takes into account each patient's clinico-biological profile to optimize the likelihood of treatment success.

What is known about this topic

  • Radioiodine therapy with iodine-131 is a widely used and effective treatment for hyperthyroidism, but treatment response remains heterogeneous;
  • Several clinical and biological factors, such as disease type, thyroid size, and antibody status, have been suggested as potential predictors of treatment outcome, though findings remain inconsistent across studies.

What this study adds

  • This study identifies higher administered doses of iodine-131 (p=0.007), TSH receptor antibody positivity (p=0.005), and the presence of ophthalmopathy (p=0.013) as significant predictors of radioiodine therapy failure after the first course;
  • It emphasises the need for individualised dosing strategies rather than a fixed-dose approach, and calls for multicenter studies to harmonise treatment protocols in Tunisia.

 

 

Competing interests Up    Down

The authors declare no competing interests.

 

 

Authors' contributions Up    Down

Conceptualisation and writing: Skander Chaabouni, Imen Meddeb, Marwa Somai and Asma Krir. Data curation and original draft: Skander Chaabouni. Methodology: Imen Meddeb, Marwa Somai and Asma Krir. Review and editing: Imen Meddeb, Marwa Somai, Asma Krir and Mehdi Mrad. Formal analysis: Asma Krir and Mehdi Mrad. Project administration, supervision and validation: Afef Bahlous and Aida Mhiri. All authors read and approved the final version of the manuscript.

 

 

Acknowledgments Up    Down

The authors had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

 

 

Tables Up    Down

Table 1: measurement techniques and reference values of studied biological parameters

Table 2: summary of factors associated with response to radioiodine therapy

Table 3: major studies evaluating predictive factors for response to radioactive iodine therapy in hyperthyroidism

 

 

References Up    Down

  1. Burch HB, Burman KD, Cooper DS. A 2011 survey of clinical practice patterns in the management of Graves' disease. J Clin Endocrinol Metab. Dec 2012;97(12):4549-58. PubMed | Google Scholar

  2. Sellem A, Elajmi W, Mhamed RB, Oueslati N, Ouertani H, Hammami H. Irathérapie dans la maladie de Basedow: place et efficacité [Role and effectiveness of radioactive-iodine therapy for the treatment of Grave's disease]. Pan Afr Med J. 2020;36:341. PubMed | Google Scholar

  3. Alvi AM, Azmat U, Shafiq W, Ali Rasheed AH, Siddiqi AI, Khan S et al. Efficacy of Radioiodine Therapy in Patients With Primary Hyperthyroidism: An Institutional Review From Pakistan. Cureus. 14(5):e24992. PubMed | Google Scholar

  4. Sundaresh V, Brito JP, Wang Z, Prokop LJ, Stan MN, Murad MH et al. Comparative effectiveness of therapies for Graves´ hyperthyroidism: a systematic review and network meta-analysis. J Clin Endocrinol Metab. Sept 2013;98(9):3671-7. PubMed | Google Scholar

  5. Corvilain B, Hamy A, Brunaud L, Borson-Chazot F, Orgiazzi J, Bensalem Hachmi L et al. Treatment of adult Graves' disease. Ann Endocrinol. Dec 2018;79(6):618-3. PubMed | Google Scholar

  6. Schneider DF, Sonderman PE, Jones MF, Ojomo KA, Chen H, Jaume JC et al. Failure of radioactive iodine in treatment of hyperthyroidism. Ann Surg Oncol. Dec 2014;21(13):4174-80. PubMed | Google Scholar

  7. El Issami S, Sarroukh F, Elrhoul M, Guerrouj H, Ghfir I, Ben Rais Aouad N. Traitement de l´hyperthyroïdie par l´iode 131 : à propos de 280 cas. Médecine Nucl. Oct 2011;35(10):528-32. Google Scholar

  8. Maji D. Hyperthyroidism. J Indian Med Assoc. Oct 2006;104(10):563-4, 566-7. PubMed

  9. Hennessey JV. Diagnosis and management of thyrotoxicosis. Am Fam Physician. Sept 1996;54(4):1315-24. PubMed | Google Scholar

  10. Feleh EE, Mahjoubi S, Bchir N, Jaidane A, Sellem A, Ouertani H. Place de l'irathérapie dans le traitement de la maladie de Basedow. Ann Endocrinol. Sept 2017;78(4):326. Google Scholar

  11. Fanning E, Inder WJ, Mackenzie E. Radioiodine treatment for graves´ disease: a 10-year Australian cohort study. BMC Endocr Disord. Dec 2018;18(1):94. PubMed | Google Scholar

  12. Ceccarelli C, Bencivelli W, Vitti P, Grasso L, Pinchera A. Outcome of radioiodine-131 therapy in hyperfunctioning thyroid nodules: a 20 years´ retrospective study. Clin Endocrinol (Oxf). 2005;62(3):331-5. PubMed | Google Scholar

  13. Reid JR, Wheeler SF. Hyperthyroidism: Diagnosis and Treatment. Am Fam Physician. Aug 2005;72(4):623-30. PubMed | Google Scholar

  14. Li H, Li J. Thyroid disorders in women. Minerva Med. Apr 2015;106(2):109-14. PubMed | Google Scholar

  15. Société Française d´Endocrinologie. Item 242 - Hyperthyroïdie. Accessed 22nd November 2023.

  16. Aung ET, Zammitt NN, Dover AR, Strachan MWJ, Seckl JR, Gibb FW. Predicting outcomes and complications following radioiodine therapy in Graves´ thyrotoxicosis. Clin Endocrinol (Oxf). Jan 2019;90(1):192-9. PubMed | Google Scholar

  17. Allahabadia A, Daykin J, Sheppard MC, Gough SC, Franklyn JA. Radioiodine treatment of hyperthyroidism-prognostic factors for outcome. J Clin Endocrinol Metab. Aug 2001;86(8):3611-7. PubMed | Google Scholar

  18. Boelaert K, Syed AA, Manji N, Sheppard MC, Holder RL, Gough SC et al. Prediction of cure and risk of hypothyroidism in patients receiving 131I for hyperthyroidism. Clin Endocrinol (Oxf). 2009;70(1):129-38. PubMed | Google Scholar

  19. Yassine I, Rchachi, El Ouahabi H, Ajdi F. Profil de la maladie de basedow au CHU de Fès:(à propos de 35 cas). Ann Endocrinol. Sept 2015;76(4):427. Google Scholar

  20. Mokhtari ME, Corvo L, Popescu M. La maladie de Basedow à propos de 20 cas. Ann Endocrinol. Sept 2015;76(4):436. Google Scholar

  21. Rezgani I, Meddeb I, Yeddeas I, Slim I, Mhiri A, Ben Slimène MF. Étude comparative de l´efficacité de l´irathérapie au cours de la maladie de Basedow et des nodules thyroïdiens toxiques. Ann Endocrinol. Sept 2017;78(4):337. Google Scholar

  22. Kaplan MM, Meier DA, Dworkin HJ. Treatment of hyperthyroidism with radioactive iodine. Endocrinol Metab Clin North Am. Mar 1998;27(1):205-23. PubMed | Google Scholar

  23. Aizawa Y, Yoshida K, Kaise N, Fukazawa H, Kiso Y, Sayama N et al. The development of transient hypothyroidism after iodine-131 treatment in hyperthyroid patients with Graves' disease: prevalence, mechanism and prognosis. Clin Endocrinol (Oxf). 1997;46(1):1-5. PubMed | Google Scholar

  24. Husseni MA. The Incidence of Hypothyroidism Following the Radioactive Iodine Treatment of Graves´ Disease and the Predictive Factors Influencing its Development. World J Nucl Med. 2016;15(1):30-7. PubMed | Google Scholar

  25. Reynolds LR, Kotchen TA. Antithyroid drugs and radioactive iodine. Fifteen years' experience with Graves´ disease. Arch Intern Med. Jun 1979;139(6):651-3. PubMed | Google Scholar

  26. Pedersen IB, Knudsen N, Perrild H, Ovesen L, Laurberg P. TSH-receptor antibody measurement for differentiation of hyperthyroidism into Graves' disease and multinodular toxic goitre: a comparison of two competitive binding assays. Clin Endocrinol (Oxf). Sept 2001;55(3):381-90. PubMed | Google Scholar

  27. John M, Jagesh R, Unnikrishnan H, Jalaja MMN, Oommen T, Gopinath D. Utility of TSH Receptor Antibodies in the Differential Diagnosis of Hyperthyroidism in Clinical Practice. Indian J Endocrinol Metab. 2022;26(1):32-7. PubMed | Google Scholar

  28. Murakami Y, Takamatsu J, Sakane S, Kuma K, Ohsawa N. Changes in thyroid volume in response to radioactive iodine for Graves´ hyperthyroidism correlated with activity of thyroid-stimulating antibody and treatment outcome. J Clin Endocrinol Metab. Sept 1996;81(9):3257-60. PubMed | Google Scholar

  29. Chiovato L, Fiore E, Vitti P, Rocchi R, Rago T, Dokic D et al. Outcome of thyroid function in Graves´ patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage. J Clin Endocrinol Metab. Jan 1998;83(1):40-6. PubMed | Google Scholar

  30. Hebaili N, El Bez I, Ben Sellem D, Meddeb I, Yeddes I, Ihssen S et al. Hypothyroidie post-radiothérapie métabolique par l´iode 131. Ann Endocrinol. Oct 2014;75(5):489. Google Scholar

  31. Braga M, Walpert N, Burch HB, Solomon BL, Cooper DS. The effect of methimazole on cure rates after radioiodine treatment for Graves´ hyperthyroidism: a randomized clinical trial. Thyroid Off J Am Thyroid Assoc. Feb 2002;12(2):135-9. PubMed | Google Scholar

  32. Kiatkittikul P, Raruenrom Y, Theerakulpisut D, Somboonporn C. Success Rate of Radioactive Iodine Therapy in Graves' Disease Using Dose Corrected for Thyroid Gland Size: Siriraj Med J. Feb 2021;73(2):108-13. Google Scholar

  33. Cherchir F, Oueslati I, Merhbène Y, Yazidi M, Amdouni A, Kallel M et al. Les anticorps anti-thyroperoxydase au cours de la maladie de Basedow: prévalence et impact sur l´évolution de la maladie. Ann Endocrinol. Oct 2023;84(5):585-6. Google Scholar

  34. Yoshida K, Aizawa Y, Kaise N, Fukazawa H, Kiso Y, Sayama N et al. Role of thyroid-stimulating blocking antibody in patients who developed hypothyroidism within one year after 131I treatment for Graves´ disease. Clin Endocrinol (Oxf). 1998;48(1):17-22. PubMed | Google Scholar

  35. Walter MA, Briel M, Christ-Crain M, Bonnema SJ, Connell J, Cooper DS et al. Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials. BMJ. Mar 2007;334(7592):514. PubMed | Google Scholar

  36. Hindié E, Ain KB, Zerdoud S, Avram AM. Discussion on radioactive iodine treatment of hyperthyroidism and the risk of induced cancer. Médecine Nucl. Oct 2020;44(4):287-9. Google Scholar

  37. Khalife A, Valdes Socin HG, Beckers A. Controverses thérapeutiques: le traitement de la maladie de Basedow. Rev Médicale Liège. Juil 1999;54(7):606-10. PubMed | Google Scholar

  38. Société Française de Médecine Nucléaire et Imagerie Moléculaire. Guide pour la rédaction de protocoles de traitement des hyperthyroïdies par iode 131. Paris: SFMN;2005.

  39. Vija Racaru L, Fontan C, Bauriaud-Mallet M, Brillouet S, Caselles O, Zerdoud S et al. Clinical outcomes 1 year after empiric 131I therapy for hyperthyroid disorders: real life experience and predictive factors of functional response. Nucl Med Commun. sept 2017;38(9):756-63. PubMed | Google Scholar

  40. Collier A. Thyrotoxicosis and radioiodine therapy: Does the dose matter. Indian J Endocrinol Metab. Dec 2012;16(Suppl 2):S147-9. PubMed | Google Scholar

  41. Ben Souda M, Halima M, Fokoue F, Salhi H, El Ouahabi H, Ismaili Alaoui N. Place de l´irathérapie dans le traitement des nodules toxiques: à propos de 76 cas. Ann Endocrinol. Sept 2018;79(4):375. Google Scholar

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Search

Volume 52 (Sep - Dec 2025)

This article authors

On Pubmed
On Google Scholar

Citation [Download]

Zotero
EndNote XML
Reference Manager
BibTex
ProCite

Navigate this article

Similar articles in

Key words

Article metrics

Countries of access

PlumX Metrics

Predictive factors of radioactive iodine therapy failure in hyperthyroidism: a retrospective study of 171 patients

Recently from the PAMJ

Incidental prostate cancer status in two tertiary centers from Kigali, Rwanda: insights from a retrospective review

Monitoring of virological response and acquired HIV-1 drug resistance among patients initiating antiretroviral therapy in the centre region of Cameroon

Investigation of the underlying causes of malnutrition among children in the Nyabihu and Ngororero districts of Rwanda: a cross-sectional descriptive survey design

Profil épidémiologique de la tuberculose dans un contexte sécuritaire difficile (2021-2023): région du Centre-Est, Burkina Faso

Frailty and associated factors among older patients with non-dialysis chronic kidney disease: a multicenter cross-sectional study in three hospitals in Yaounde, Cameroon

Access to medicines for the management of asthma in Nigeria: is it getting worse?

Authors´ services